J Policy Anal Manage. 2015 Summer;34(3):639-96.
Tuesday, June 30, 2015
J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):466-73. doi: 10.1097/QAI.0000000000000616.
Psychol Sci. 2015 Jun 26. pii: 0956797615586188. [Epub ahead of print]
Monday, June 29, 2015
J Perinat Med. 2015 Jun 26. pii: /j/jpme.ahead-of-print/jpm-2015-0152/jpm-2015-0152.xml. doi: 10.1515/jpm-2015-0152. [Epub ahead of print]
Thursday, June 25, 2015
Washington, DC — Jun 25, 2015, 11:42 AM ET
“Obamacare has never been accepted by the American people,” Johnson said. “The harm that the law inflicts shows that the people were right. Congress must move America past this unaffordable, destructive law.”
Justice Scalia’s final paragraph in his dissent today in King v. Burwell pretty much says it all. Read the opinion and weep.
"...the Supreme Court of the United States favors some laws over others, and is prepared to do whatever it takes to uphold and assist its favorites."
In siding with the administration in King v. Burwell, the justices deal a blow to opponents of the Affordable Care Act.
"King v. Burwell centered on whether plaintiffs' arguments that middle- and low-income adults who purchased health insurance through the federally run Healthcare.gov marketplace were entitled to subsidies based on the language of the law that says tax credits are only to be distributed for marketplaces 'established by the state.'"
Wednesday, June 24, 2015
Safety and Efficacy of Buparlisib (BKM120) in Patients With PI3K Pathway-Activated Non-Small Cell Lung Cancer (NSCLC): Results From the Phase II BASALT-1 Study
J Thorac Oncol. 2015 Jun 19. [Epub ahead of print]
Safety and Efficacy of Buparlisib (BKM120) in Patients With PI3K Pathway-Activated Non-Small Cell Lung Cancer (NSCLC): Results From the Phase II BASALT-1 Study.
Vansteenkiste JF1, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P,Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC.
The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibitor buparlisib (BKM120) in patients with PI3K pathway-activated, relapsed NSCLC.
Oncotarget. 2015 Jun 10. [Epub ahead of print]
J Med Ethics. 2015 Jun 22. pii: medethics-2014-102651. doi: 10.1136/medethics-2014-102651. [Epub ahead of print]